65 related articles for article (PubMed ID: 2459233)
1. Association of cytoskeletal re-organization with capping of the complement decay-accelerating factor on T lymphocytes.
Kammer GM; Walter EI; Medof ME
J Immunol; 1988 Nov; 141(9):2924-8. PubMed ID: 2459233
[TBL] [Abstract][Full Text] [Related]
2. Endocytosis and shedding of the decay accelerating factor on human polymorphonuclear cells.
Tausk F; Fey M; Gigli I
J Immunol; 1989 Nov; 143(10):3295-302. PubMed ID: 2478622
[TBL] [Abstract][Full Text] [Related]
3. Patterns of costimulation of T cell clones by cross-linking CD3, CD4/CD8, and class I MHC molecules.
Wacholtz MC; Patel SS; Lipsky PE
J Immunol; 1989 Jun; 142(12):4201-12. PubMed ID: 2470819
[TBL] [Abstract][Full Text] [Related]
4. Internalization of phosphatidylinositol-anchored lymphocyte proteins. I. Documentation and potential significance for T cell stimulation.
Bamezai A; Goldmacher V; Reiser H; Rock KL
J Immunol; 1989 Nov; 143(10):3107-16. PubMed ID: 2572642
[TBL] [Abstract][Full Text] [Related]
5. Decay-accelerating factor functions as a signal transducing molecule for human T cells.
Davis LS; Patel SS; Atkinson JP; Lipsky PE
J Immunol; 1988 Oct; 141(7):2246-52. PubMed ID: 2459203
[TBL] [Abstract][Full Text] [Related]
6. Comparative studies of decay-accelerating factor and HLA-DR within the CD8-brightly positive population.
Tomita A; Okada N; Okada H
Eur J Immunol; 1991 Aug; 21(8):1843-8. PubMed ID: 1714392
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cells are deficient in the surface expression of the complement regulatory protein, decay accelerating factor (DAF).
Nicholson-Weller A; Russian DA; Austen KF
J Immunol; 1986 Aug; 137(4):1275-9. PubMed ID: 3090145
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for variations in the sensitivity of human decay accelerating factor to phosphatidylinositol-specific phospholipase C cleavage.
Walter EI; Roberts WL; Rosenberry TL; Ratnoff WD; Medof ME
J Immunol; 1990 Feb; 144(3):1030-6. PubMed ID: 1688588
[TBL] [Abstract][Full Text] [Related]
9. Cell surface comodulation of CD4 and T cell receptor by anti-CD4 monoclonal antibody.
Cole JA; McCarthy SA; Rees MA; Sharrow SO; Singer A
J Immunol; 1989 Jul; 143(2):397-402. PubMed ID: 2786906
[TBL] [Abstract][Full Text] [Related]
10. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
Iwata K; Seya T; Ariga H; Nagasawa S
J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
[TBL] [Abstract][Full Text] [Related]
11. Cytokine-mediated regulation of the surface expression of complement regulatory proteins, CD46(MCP), CD55(DAF), and CD59 on human vascular endothelial cells.
Moutabarrik A; Nakanishi I; Namiki M; Hara T; Matsumoto M; Ishibashi M; Okuyama A; Zaid D; Seya T
Lymphokine Cytokine Res; 1993 Jun; 12(3):167-72. PubMed ID: 7688580
[TBL] [Abstract][Full Text] [Related]
12. Purification and characterization of decay-accelerating factor (DAF) from Raji cells.
Fujita T; Shinkai Y; Inoue T; Tamura N
Immunology; 1988 Jul; 64(3):369-74. PubMed ID: 2457546
[TBL] [Abstract][Full Text] [Related]
13. Expression of decay-accelerating factor (CD55) of the complement system on human spermatozoa.
Cervoni F; Oglesby TJ; Fénichel P; Dohr G; Rossi B; Atkinson JP; Hsi BL
J Immunol; 1993 Jul; 151(2):939-48. PubMed ID: 7687624
[TBL] [Abstract][Full Text] [Related]
14. Stimulation via the CD3 and CD28 molecules induces responsiveness to IL-4 in CD4+CD29+CD45R- memory T lymphocytes.
Damle NK; Doyle LV
J Immunol; 1989 Sep; 143(6):1761-7. PubMed ID: 2570801
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of autologous antibodies and decay-accelerating factor, an inhibitor of complement, on human renal tumor cells.
Terachi T; Stanescu G; Pontes JE; Medof ME; Caulfield MJ
Cancer Res; 1991 May; 51(10):2521-3. PubMed ID: 1708695
[TBL] [Abstract][Full Text] [Related]
16. Additional forms of human decay-accelerating factor (DAF).
Seya T; Farries T; Nickells M; Atkinson JP
J Immunol; 1987 Aug; 139(4):1260-7. PubMed ID: 2440950
[TBL] [Abstract][Full Text] [Related]
17. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor.
Brodbeck WG; Liu D; Sperry J; Mold C; Medof ME
J Immunol; 1996 Apr; 156(7):2528-33. PubMed ID: 8786315
[TBL] [Abstract][Full Text] [Related]
18. Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor.
Martino TA; Petric M; Brown M; Aitken K; Gauntt CJ; Richardson CD; Chow LH; Liu PP
Virology; 1998 May; 244(2):302-14. PubMed ID: 9601501
[TBL] [Abstract][Full Text] [Related]
19. Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis.
Mason JC; Lidington EA; Yarwood H; Lublin DM; Haskard DO
Arthritis Rheum; 2001 Jan; 44(1):138-50. PubMed ID: 11212152
[TBL] [Abstract][Full Text] [Related]
20. Decay-accelerating factor on human umbilical vein endothelial cells. Its histamine-induced expression and spontaneous rapid shedding from the cell surface.
Tsuji S; Kaji K; Nagasawa S
J Immunol; 1994 Feb; 152(3):1404-10. PubMed ID: 7507966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
